SCHEMBL1715342

SCHEMBL1715342

NOCCNS(=O)(=O)Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
HPGD P15428 2/20 0.56
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
MMP1 P03956 1/20 0.52
MMP2 P08253 1/20 0.52
MMP9 P14780 1/20 0.52
MMP8 P22894 1/20 0.52
MMP13 P45452 1/20 0.52
CA5A P35218 1/20 0.47
CA9 Q16790 1/20 0.47
CYP19A1 P11511 1/20 0.46
PGR P06401 1/20 0.45
IDO1 P14902 1/20 0.44
AR P10275 1/20 0.44
KDM4E B2RXH2 1/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1715419 0.90 ALDH1A1 (0.66) ALDH1A1HPGDCA1CA2MMP1
SCHEMBL9065937 0.84 ALDH1A1 (0.67) ALDH1A1HPGDCA1CA2MMP1
SCHEMBL1998286 0.82 ALDH1A1 (0.60) ALDH1A1HPGDCA1CA2MMP1
SCHEMBL9322614 0.81 ALDH1A1 (0.55) ALDH1A1HPGDCA1CA2MMP1
SCHEMBL819258 0.79 CA1 (0.57) ALDH1A1HPGDCA1CA2MMP1
SCHEMBL4600688 0.78 ALDH1A1 (0.56) ALDH1A1HPGDCA1CA2MMP1
Hydrochloric Acid SCHEMBL11655904 0.78 CA1 (0.55) ALDH1A1HPGDCA1CA2MMP1
SCHEMBL603913 0.77 CA1 (0.59) ALDH1A1HPGDCA1CA2MMP1
SCHEMBL4601440 0.77 CA1 (0.59) ALDH1A1HPGDCA1CA2MMP1
SCHEMBL6262776 0.77 ALDH1A1 (0.51) ALDH1A1HPGDCA1CA2MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US claimed
JP-2007513098-A 2007-05-24 JP claimed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO claimed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 ALDH1A1 804/4885HPGD 301/4885CA1 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.